.

Deeper Knowledge, Faster

  • Find suppliers and generic API sources
  • Predict branded drug patent expiration
  • Obtain formulation and manufacturing information

► See Plans & Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving 500+ biopharmaceutical companies globally:

Daiichi Sankyo
Teva
Citi
Healthtrust
Julphar
Dow
Moodys
Baxter
Novartis
Harvard Business School

Generated: June 26, 2017

DrugPatentWatch Database Preview

COMMIT Drug Profile

« Back to Dashboard

Which patents cover Commit, and what generic Commit alternatives are available?

Commit is a drug marketed by Glaxosmithkline Cons and is included in one NDA.

The generic ingredient in COMMIT is nicotine polacrilex. There are twenty-nine drug master file entries for this compound. Forty-five suppliers are listed for this compound. Additional details are available on the nicotine polacrilex profile page.

Summary for Tradename: COMMIT

Patents:0
Applicants:1
NDAs:1
Suppliers / Packagers: see list3
Bulk Api Vendors: see list51
Clinical Trials: see list32
Patent Applications: see list8,006
Formulation / Manufacturing:see details
Drug Prices:see details
DailyMed Link:COMMIT at DailyMed
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Glaxosmithkline Cons
COMMIT
nicotine polacrilex
TROCHE/LOZENGE;ORAL021330-001Oct 31, 2002OTCYesNo► Subscribe► Subscribe
Glaxosmithkline Cons
COMMIT
nicotine polacrilex
TROCHE/LOZENGE;ORAL021330-002Oct 31, 2002OTCYesYes► Subscribe► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Expired Patents for Tradename: COMMIT

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Glaxosmithkline Cons
COMMIT
nicotine polacrilex
TROCHE/LOZENGE;ORAL021330-001Oct 31, 20025,110,605► Subscribe
Glaxosmithkline Cons
COMMIT
nicotine polacrilex
TROCHE/LOZENGE;ORAL021330-002Oct 31, 20025,110,605► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

Serving 500+ biopharmaceutical companies globally:

QuintilesIMS
Novartis
US Army
Express Scripts
Moodys
Cipla
Fuji
US Department of Justice
Dow
Federal Trade Commission

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted

Follow DrugPatentWatch:



Google
Twitter
Google Plus
botpot